{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:35:15Z","timestamp":1790976915638,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":1100,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41379-019-0327-4","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T11:04:39Z","timestamp":1565003079000},"page":"4-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["\u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy"],"prefix":"10.1016","volume":"33","author":[{"given":"Emina","family":"Torlakovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun J.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Bigras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Haeng","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-490X","authenticated-orcid":false,"given":"Pierre O.","family":"Fiset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2014-1236","authenticated-orcid":false,"given":"Marius","family":"Ilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-6685","authenticated-orcid":false,"given":"Enrico","family":"Munari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne J.","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4397","authenticated-orcid":false,"given":"David L.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"R\u00f8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-1646","authenticated-orcid":false,"given":"Andreas H.","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tretiakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka F.","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad W.","family":"Vainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-019-0327-4_bib1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-019-0327-4_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-019-0327-4_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1038\/s41379-019-0327-4_bib5","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-019-0327-4_bib6","first-page":"7","article-title":"Diagnostic accuracy in fit-for-purpose PD-L1 testing","volume":"00","author":"Cheung","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-019-0327-4_bib7","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","article-title":"Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer","volume":"35","author":"B\u00fcttner","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5858\/arpa.2015-0506-SA","article-title":"Programmed death ligand-1 immunohistochemistry\u2014a new challenge for pathologists: A Perspective From Members of the Pulmonary Pathology Society","volume":"140","author":"Sholl","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-019-0327-4_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaoncol.2015.4685","article-title":"PD-L1 testing in cancer: challenges in companion diagnostic development","volume":"2","author":"Hansen","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13000-018-0689-9","article-title":"PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics","volume":"13","author":"Udall","year":"2018","journal-title":"Diagn Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib11","unstructured":"Garrett PE, Lasky FD, Meier KL, et al. User protocol for evaluation of qualitative test performance: approved guideline. Wayne, Pa.: Clinical and Laboratory Standards Institute; 2008."},{"key":"10.1038\/s41379-019-0327-4_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1038\/s41379-019-0327-4_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1038\/s41379-019-0327-4_bib14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1398-9995.2009.02083.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies","volume":"64","author":"Bro\u017cek","year":"2009","journal-title":"Allergy"},{"key":"10.1038\/s41379-019-0327-4_bib15","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1398-9995.2010.02530.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations: GRADE: strength of recommendations in guidelines","volume":"66","author":"Bro\u017cek","year":"2011","journal-title":"Allergy"},{"key":"10.1038\/s41379-019-0327-4_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1038\/s41379-019-0327-4_bib17","doi-asserted-by":"crossref","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"10.1038\/s41379-019-0327-4_bib18","doi-asserted-by":"crossref","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.","DOI":"10.1136\/bmj.h5527"},{"key":"10.1038\/s41379-019-0327-4_bib19","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-16-1821","article-title":"PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison","volume":"23","author":"Sunshine","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-019-0327-4_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/his.13056","article-title":"Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system","volume":"70","author":"Schats","year":"2017","journal-title":"Histopathology"},{"key":"10.1038\/s41379-019-0327-4_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.humpath.2017.08.010","article-title":"PD-L1 in breast cancer: comparative analysis of 3 different antibodies","volume":"72","author":"Karnik","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib23","doi-asserted-by":"crossref","unstructured":"Xu H, Lin G, Huang C, et al. Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer. Sci Rep 2017;7. Available at: http:\/\/www.nature.com\/articles\/s41598-017-17034-5. (Accessed July 26, 2018).","DOI":"10.1038\/s41598-017-17034-5"},{"key":"10.1038\/s41379-019-0327-4_bib24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non\u2013small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib26","doi-asserted-by":"crossref","first-page":"77415","DOI":"10.18632\/oncotarget.20492","article-title":"Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-019-0327-4_bib27","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib28","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.18632\/oncotarget.23827","article-title":"Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples","volume":"9","author":"Soo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-019-0327-4_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jtho.2017.11.112","article-title":"Comparison of four PD-L1 immunohistochemical assays in lung cancer","volume":"13","author":"Hendry","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtho.2017.11.123","article-title":"Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non\u2013small cell lung cancer","volume":"13","author":"Fujimoto","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib31","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41379-018-0053-3","article-title":"Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma","volume":"31","author":"Chan","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib32","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mdy014","article-title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","volume":"29","author":"Adam","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/modpathol.2017.188","article-title":"Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression","volume":"31","author":"Tretiakova","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib34","first-page":"6","article-title":"PD-L1 assays 22C3 and SP263 are not interchangeable in non\u2013small cell lung cancer when considering clinically relevant cutoffs","volume":"00","author":"Munari","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib35","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jtho.2016.08.146","article-title":"A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform","volume":"11","author":"Neuman","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/PAI.0000000000000534","article-title":"Accurate PD-L1 protocols for non\u2013small cell lung cancer can be developed for automated staining platforms with clone","volume":"25","author":"R\u00f8ge","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-019-0327-4_bib37","doi-asserted-by":"crossref","first-page":"e0183023","DOI":"10.1371\/journal.pone.0183023","article-title":"Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms","volume":"12","author":"Ilie","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1038\/s41379-019-0327-4_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cncy.21977","article-title":"Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients: PD-L1 22C3 Cytology-Based LDTs in NSCLC","volume":"126","author":"Ilie","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"10.1038\/s41379-019-0327-4_bib39","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non\u2013Small Cell Lung Cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-019-0327-4_bib40","doi-asserted-by":"crossref","first-page":"20769","DOI":"10.18632\/oncotarget.25100","article-title":"Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma","volume":"9","author":"Watanabe","year":"2018","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-019-0327-4_bib41","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.18632\/oncotarget.24075","article-title":"A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma","volume":"9","author":"Sakane","year":"2018","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-019-0327-4_bib42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/jclinpath-2018-205362","article-title":"A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies","volume":"71","author":"Batenchuk","year":"2018","journal-title":"J Clin Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib43","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41379-018-0071-1","article-title":"Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms","volume":"31","author":"Koppel","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib44","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1002\/sim.3441","article-title":"Meta-analysis of diagnostic test studies using individual patient data and aggregate data","volume":"27","author":"Riley","year":"2008","journal-title":"Stat Med"},{"key":"10.1038\/s41379-019-0327-4_bib45","unstructured":"Sutton AJ, Abrams KR, Jones DR, et al. Methods for Meta-Analysis for Medical Research. John Wiley & Sons, Ltd.; 2000."},{"key":"10.1038\/s41379-019-0327-4_bib46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1038\/s41379-019-0327-4_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/ije\/31.1.88","article-title":"Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy","volume":"31","author":"Song","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1038\/s41379-019-0327-4_bib48","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.5858\/arpa.2013-0610-CP","article-title":"Principles of analytic validation of immunohistochemical assays: guideline from the college of American Pathologists Pathology and Laboratory Quality Center","volume":"138","author":"Fitzgibbons","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-019-0327-4_bib49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","article-title":"Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue","volume":"140","author":"Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1038\/s41379-019-0327-4_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/PAI.0000000000000594","article-title":"Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab","volume":"27","author":"Vennapusa","year":"2019","journal-title":"Applied Immunohistochemistry & Molecular Morphology"},{"key":"10.1038\/s41379-019-0327-4_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13000-016-0545-8","article-title":"Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"11","author":"Rebelatto","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib52","doi-asserted-by":"crossref","unstructured":"Phillips T, Millett MM, Zhang X, et al. Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma: Appl Immunohistochem Mol Morphol 2018;26:6\u201312.","DOI":"10.1097\/PAI.0000000000000605"},{"key":"10.1038\/s41379-019-0327-4_bib53","first-page":"392","volume":"24","author":"Roach","year":"2016","journal-title":"Dev a Companion Diagn PD-L1 Immunohistochem Assay Pembrolizumab Ther Non\u2013Small-cell Lung Cancer: Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-019-0327-4_bib54","first-page":"4","article-title":"Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers","volume":"25","author":"Cheung","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"key":"10.1038\/s41379-019-0327-4_bib55","first-page":"7","article-title":"Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine \u2013 Part 2: Immunohistochemistry Test Performance Characteristics","volume":"25","author":"Torlakovic","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-019-0327-4_bib56","first-page":"9","article-title":"Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories","volume":"00","author":"Torlakovic","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-019-0327-4_bib57","first-page":"4","article-title":"Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry","volume":"00","author":"Cheung","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-019-0327-4_bib58","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/95.8.628","article-title":"Re: HER2 Testing in the Real World","volume":"95","author":"Vincent-Salomon","year":"2003","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1038\/s41379-019-0327-4_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00428-015-1829-1","article-title":"Proficiency testing in immunohistochemistry\u2013experiences from Nordic Immunohistochemical Quality Control (NordiQC)","volume":"468","author":"Vyberg","year":"2016","journal-title":"Virchows Arch Int J Pathol"},{"key":"10.1038\/s41379-019-0327-4_bib60","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.jtho.2016.07.012","article-title":"ALK immunohistochemistry in NSCLC: discordant staining can impact patient treatment regimen","volume":"11","author":"Ibrahim","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/94.11.855","article-title":"Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831","volume":"94","author":"Roche","year":"2002","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1038\/s41379-019-0327-4_bib62","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10549-016-4061-z","article-title":"Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample","volume":"161","author":"Griggs","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-019-0327-4_bib63","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.03.008","article-title":"Biosimilars in Oncology: From Development to Clinical Practice","volume":"41","author":"Rak Tkaczuk","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1038\/s41379-019-0327-4_bib64","unstructured":"Babbitt B, Nick C Considerations in Establishing a US Approval Pathway for Biosimilar and Interchangeable Biological Products. Biosimilars. https:\/\/www.parexel.com\/application\/files_previous\/8713\/8868\/2664\/PRXL_Key_Considerations_in_US_Biosimilars_Development.pdf. (Accessed June 16, 2019)."},{"key":"10.1038\/s41379-019-0327-4_bib65","unstructured":"U.S. Food and Drug Administratioin. Biosimilar Development, Review, and Approval. 2017. Available at: Biosimilar Development, Review, and Approval. (Accessed December 21, 2018)."},{"key":"10.1038\/s41379-019-0327-4_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/08941930903469508","article-title":"Guidelines for diagnostic tests and diagnostic accuracy in surgical research","volume":"23","author":"Jones","year":"2010","journal-title":"J Invest Surg"},{"key":"10.1038\/s41379-019-0327-4_bib67","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1038\/s41379-019-0327-4_bib68","first-page":"203","article-title":"Measures of diagnostic accuracy: basic definitions","volume":"19","author":"Simundic","year":"2009","journal-title":"EJIFCC"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0327-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0327-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222009401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222009401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0327-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:44:25Z","timestamp":1760229865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222009401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0893395222009401"],"URL":"https:\/\/doi.org\/10.1038\/s41379-019-0327-4","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-019-0327-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors.","name":"copyright","label":"Copyright"}]}}